Post by Kupando GmbH

Kupando GmbH closes €23 million Series A to advance KUP101 into clinical trials. We are proud to announce the successful closing of an additional €10 million in Series A financing, bringing our total round to €23 million. This funding marks a transformative moment for Kupando as we prepare to initiate our Phase 1b clinical study for our lead candidate, KUP101, in advanced solid tumors. Additionally, this capital will accelerate our preclinical programs in infectious diseases. A sincere thank you to our lead investor Remiges Ventures, Inc., co-lead LifeCare Partners, and our existing syndicate for their continued trust – among which Brandenburg Kapital GmbH, HTGF | High-Tech Gründerfonds and Ventura BioMed Investors. We are also delighted to welcome Carma Fund to the Kupando family. By harnessing the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists, we are redefining the treatment paradigm for oncology and infectious diseases. The full announcement is available here: https://lnkd.in/dsAwsCvr #Biotech #SeriesA #ClinicalTrials #Oncology #InfectiousDiseases #Immunotherapy #Kupando